Assessment of Admission to the ICU of Onco-hematological Patients.

Assessment of Admission to the ICU of Onco-hematological Patients. Income Patterns and Results.

Multicenter, observational and prospective study.

Study Overview

• Status: Not yet recruiting
• Conditions: Critical Illness; Hematological Diseases
• Intervention / Treatment: Other: There is no intervention.

Detailed Description

The data collection period will include 6 consecutive months, starting from the date of acceptance or conformity of the CEIC. Or, until an adequate sample size is reached that guarantees the statistical relevance of said analysis. All patients will subsequently be followed up 3 months after discharge from the ICU.

• Study Type: Observational
• Enrollment (Estimated): 800

Contacts and Locations

• Study Contact: Name: Elena Cuenca Fito; Phone Number: 647113703; Email: ecuencafito@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Patients with a diagnosis of solid organ or hematological tumor who are admitted to the hospital and require ICU evaluation.

Description

Inclusion Criteria:

• Adults
• Solid organ tumor or hematological malignancy,

Exclusion Criteria:

-under 18 years old

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients admitted to the ICU.	Other: There is no intervention.; There is no intervention in the study.
Patients who are not admitted to the ICU.	Other: There is no intervention.; There is no intervention in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Hospital mortality.	During the 6 months of the study.

Collaborators and Investigators

• Sponsor: University Hospital A Coruña

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2024
• Primary Completion (Estimated): July 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: July 11, 2023
• First Submitted That Met QC Criteria: November 1, 2023
• First Posted (Actual): November 2, 2023

Study Record Updates

• Last Update Posted (Actual): November 2, 2023
• Last Update Submitted That Met QC Criteria: November 1, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Hematologic Diseases; Critical Illness
• Other Study ID Numbers: 23772377

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No